Arvinas plummets after late-stage data from breast cancer treatment

Arvinas

11/03/2025 11:47

** Drug developer Arvinas' ARVN.O shares fall 39% to $10.70 premarket

** Pfizer PFE.N and ARVN say their experimental breast cancer treatment helped significantly improve the time some patients lived without the disease worsening, but failed to achieve statistically significant results in others

** The drug, vepdegestrant, was tested in patients with a type of advanced breast cancer whose disease progressed following prior treatment

** Arvinas says the drug failed to show statistically significant improvements in the intent-to-treat population during the late-stage trial

** As of last close, ARVN down 62.7% in past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))